



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Correction

Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies

Daniel Wrapp, Dorien De Vlieger, Kizzmekia S. Corbett, Gretel M. Torres, Nianshuang Wang, Wander Van Breedam, Kenny Roose, Loes van Schie, VIB-CMB COVID-19 Response Team, Markus Hoffmann, Stefan Pöhlmann, Barney S. Graham, Nico Callewaert, Bert Schepens, *Xavier Saelens,* and Jason S. McLellan*

*Correspondence: bert.schepens@vib-ugent.be (B.S.), xavier.saelens@vib-ugent.be (X.S.), jmclellan@austin.utexas.edu (J.S.M.)
<https://doi.org/10.1016/j.cell.2020.05.047>

(Cell 181, 1004–1015.e1–e15; May 28, 2020)

We recently discovered that two early batches of purified monovalent SARS VHH protein samples were switched during the expression in *Pichia pastoris*. Although this error had no effect on the biophysical or structural work, nor on the SARS-CoV-1 and –2 cross-reactivity and cross-neutralization demonstrated with the bivalent fusion constructs, and our conclusions remain unchanged, several figures (Figures 1A, 6A–6D, S1C, S3, S6D and S6E), one table (Table S1), and the corresponding text have been amended in the online and print versions to correct this. We apologize for any confusion that this error may have caused.




Figure 1. Epitope Determination and Biophysical Characterization of MERS VHH-55 and SARS VHH-72 (corrected)




Figure 1. Epitope Determination and Biophysical Characterization of MERS VHH-55 and SARS VHH-72 (original)




Figure 6. SARS VHH-72 Bivalency Permits SARS-CoV-2 Pseudovirus Neutralization (corrected)




Figure 6. SARS VHH-72 Bivalency Permits SARS-CoV-2 Pseudovirus Neutralization (original)




Figure S1. CoV VHH Immunization and Panning (corrected)




Figure S1. CoV VHH Immunization and Panning (original)




Figure S3. Lack of Binding of MERS-CoV and SARS-CoV-Directed VHHS to Non-RBD Epitopes (corrected)




Figure S3. Lack of Binding of MERS-CoV and SARS-CoV-Directed VHHs to Non-RBD Epitopes (original)




Figure S6. Engineering a Functional Bivalent VHH Construct (corrected)




Figure S6. Engineering a Functional Bivalent VHH Construct (original)